mRNA technology

An FDA panel recommended approval of Moderna's first mRNA-based flu vaccine, mFlusiva, for adults aged 50 and older, citing its benefits outweighing risks. The vaccine, developed using technology similar to COVID-19 vaccines, showed a 27% reduction in flu cases compared to traditional vaccines in clinical trials and is under final FDA review for potential approval by August.

The FDA is considering Moderna's first mRNA-based flu vaccine, mFlusiva, for people 50 and older. A study showed it reduced flu cases by 27% compared to a standard vaccine, but data on frail older adults and those with weak immune systems is lacking. A prior FDA official disputed the vaccine's comparison to a high-dose brand, but the application was later accepted.

The FDA advisory panel is evaluating Moderna's first mRNA-based flu vaccine, mFlusiva, for approval in adults 50 and older. The vaccine, which showed a 27% reduction in flu cases compared to a standard-dose vaccine in a 40,000-person study, faces scrutiny over its study design but has received a favorable FDA review with no safety concerns noted.

The FDA is considering Moderna's first mRNA-based flu vaccine, mFlusiva, for adults 50 and older. A study showed it reduced flu cases by 27% compared to a standard vaccine, but lacks data on very frail older adults. The decision follows a dispute with a former FDA official who questioned the study's design.